MUC1 and breast carcinoma: Furthermore, a Phase III clinical trial conducted using MUC1 for treating patients with ER+ stage 2 breast cancer showed that the MUC1-vaccine-treated group displayed a significantly reduced recurrence rate (12.5%) compared to the placebo control (60%) [117].